Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Teichman

Podiatrist, Foot & Ankle Surgery Allentown, PA Doctor of Podiatric Medicine

NPI 1043203656 CMS profile 92200

2895 Hamilton Boulevard, Suite 101, Allentown, PA 18104

Open in the dashboard

General payments

$544,593

1,156 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Teichman of Allentown, PA is reported in the CMS Open Payments database as having received $544,593 across 1,156 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53,623 117
2024 General $65,879 126
2023 General $126,825 215
2022 General $162,007 297
2021 General $45,597 151
2020 General $32,431 109
2019 General $58,231 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Teichman
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Adam Teichman were reported at $53,623. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Adam Teichman Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $58,231 $389 $118–$1,406 $163
2020 $32,431 $191 $62–$691 $114
2021 $45,597 $329 $104–$1,341 $132
2022 $162,007 $419 $125–$1,611 $149
2023 $126,825 $377 $128–$1,164 $160
2024 $65,879 $394 $134–$1,168 $164
2025 $53,623 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $223,860 456 payments
  2. Averitas Pharma Inc. $177,360 244 payments
  3. GRT US Holding, Inc. $132,105 183 payments
  4. Stryker Corporation $3,694 44 payments
  5. Horizon Therapeutics plc $1,848 73 payments
  6. ConvaTec Inc. $1,695 20 payments
  7. Smith+Nephew, Inc. $1,460 51 payments
  8. Nevro Corp. $426 16 payments
  9. Next Science LLC $392 4 payments
  10. Reapplix Inc. $346 12 payments
  11. Other $1,406 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $233,208 86 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $136,199 150 payments
  3. Travel and Lodging $98,474 391 payments
  4. Consulting Fee $53,972 24 payments
  5. Food and Beverage $22,725 504 payments
  6. Entertainment $16 1 payment
Products named General payments · program years 2019–2025
  1. Qutenza $309,465 427 payments
  2. Puraply $68,814 158 payments
  3. Apligraf Podiatry $57,772 127 payments
  4. Puraply/Affinity/NuTech $57,772 127 payments
  5. Dermagraft $57,772 127 payments
  6. Puraply Antimicrobial $39,323 86 payments
  7. Affinity $33,093 54 payments
  8. PURAPLY WOUND MATRIX $18,012 23 payments
  9. Apligraf Wound Care $7,983 7 payments
  10. NuShield $1,615 3 payments
  11. Other $20,453 424 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

254

Median for Podiatry: 160

Drug cost

$90,580

Median for Podiatry: $2,368

Branded share of claims

18.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qutenza Capsaicin/Skin Cleanser Brand 21 $76,774
Santyl Collagenase Clostridium Hist. Brand 13 $7,516
Lidocaine Generic 21 $4,601
Ammonium Lactate Generic 18 $367
Diclofenac Sodium Generic 18 $345
Ciclopirox Generic 20 $211
Doxycycline Hyclate Generic 25 $195
Methylprednisolone Generic 37 $164
Gabapentin Generic 29 $158
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $95

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$216,624

Of which drugs: $52,320

Medicare patients

274

Average age 74

Services billed

22,215

143 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 47%
Chronic kidney disease 37%
Ischemic heart disease 29%
Atrial fibrillation 20%
Depression 19%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 440 $43
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 22 170 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
$61,745 21 —
REGRANEX
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record